American regulators have approved the first gene therapy capable of restoring hearing in people born deaf, a decision that redefines the frontier of treatment for genetic hearing loss. The Food and Drug Administration authorised the therapy, Otarmeni, for children and adults with severe to profound deafness caused by specific mutations in the OTOF gene. Developed by the biotechnology company Regeneron, the one-off infusion uses a pioneering dual-vector system of harmless viruses to deliver a working copy of the gene directly into the hair cells of the inner ear, enabling them to transmit sound signals to the brain. Officials in Washington described the treatment as “groundbreaking”, an unusually emphatic term for a regulatory announcement that underscores the moment’s significance.

The approval coincides with the publication of long-term trial results from China, where another OTOF-targeted gene therapy delivered durable hearing gains. In a study spanning two and a half years, 90 percent of recipients experienced measurable improvement, and half attained normal hearing thresholds by the trial’s conclusion. The strongest responses occurred in patients aged 18 and younger, though adults also benefited, according to the findings reported in Nature by researchers from Mass Eye and Ear in Boston. From Beijing, the data confirm not only initial efficacy but sustained real-world gains, including improved speech recognition — a critical marker of functional hearing that eludes traditional cochlear implants.

Viewed from Boston, where scientists have pursued gene-based hearing restoration for decades, the dual announcements represent a historical inflection point. Zheng-Yi Chen, an associate scientist at Mass Eye and Ear who led the China trial but was not involved in the FDA-approved therapy, called the regulatory milestone a landmark development for the entire field. Analysts in London note, however, that the immediate patient population is exceptionally narrow: the OTOF defect accounts for only a tiny fraction of congenital deafness, affecting an estimated 50 newborns each year in the United States. The mutation disables otoferlin, a protein essential for relaying auditory information, and its scarcity has long tempered commercial interest.

Nevertheless, the achievement catalyses a broader push. Gene mutations underlie roughly half of all early childhood deafness, and researchers have already identified around 200 culpable genes. The dual-vector technique validated by Otarmeni could, in principle, be adapted to target other genetic errors responsible for more prevalent forms of hearing loss. Regulators in Asia and Europe will now scrutinise the evidence, with Beijing’s clinical data likely to inform forthcoming submissions. The precedent also intensifies the urgency of expanding newborn genetic screening, as the therapy’s most dramatic benefits appear when administered early.

For a condition long managed through amplification and surgery rather than biologically corrected, the advent of a one-time intervention upends decades of therapeutic nihilism. Pricing and reimbursement negotiations have not been disclosed, but the expected cost will test health systems’ willingness to fund high-priced curative genetic medicines for ultra-rare conditions. In Washington, the FDA’s endorsement provides a regulatory template; in laboratories from Shanghai to Cambridge, the race to extend the principle to more common genetic deafness is accelerating. The sound of a previously unattainable goal is now unmistakable.